ESSA Pharma (EPIX) - 2024 Q3 - Quarterly Results

Exhibit 99.1 ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024 On track to report updated Phase 1 masofaniten plus enzalutamide dose escalation data in patients with mCRPC naïve to second generation antiandrogens in the second half of 2024 Presentation of Phase 1b monotherapy results expected to be reported in the second half of 2024 Phase 2 dose expansion underway evaluating masofaniten plus enzalutamide in patients with mCRPC naïve to second g ...